Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma

Andy Chen, Jessica T. Leonard, Craig Okada, Nathan D. Gay, Kari Chansky, Guang Fan, Jennifer Dunlap, Phil Raess, Rita Braziel, Alex Stentz, Richard Maziarz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42% of cases. At median follow-up of 38 months, the 2-year progression free survival (PFS) and overall survival (OS) were 69% (95% CI 54–84%) and 71% (95% CI 56–86%). Eight cases were refractory to induction with 1-year OS 20%, and no factors were predictive for primary refractory disease. Of 28 responders, 17 proceeded to transplant while 11 were observed, primarily due to age and co-morbidities. By 24-week landmark analysis after diagnosis, the 2-year PFS and OS were both 94% (95% CI 83–100%) vs 79% (95% CI 52–100%) for transplant vs observation (p = .59 for both PFS and OS). There was no significant benefit to consolidative transplant in our series, and primary refractory DHL needs novel approaches.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Dec 4 2017

Fingerprint

Autografts
Vincristine
Etoposide
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Lymphoma
Transplants
Carmustine
Melphalan
Cytarabine
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Observation
Morbidity
Rituximab

Keywords

  • autologous transplant
  • Double hit lymphoma
  • EPOCH-R

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. / Chen, Andy; Leonard, Jessica T.; Okada, Craig; Gay, Nathan D.; Chansky, Kari; Fan, Guang; Dunlap, Jennifer; Raess, Phil; Braziel, Rita; Stentz, Alex; Maziarz, Richard.

In: Leukemia and Lymphoma, 04.12.2017, p. 1-6.

Research output: Contribution to journalArticle

@article{227256449823401dabdea12accb50ed8,
title = "Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma",
abstract = "High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42{\%} of cases. At median follow-up of 38 months, the 2-year progression free survival (PFS) and overall survival (OS) were 69{\%} (95{\%} CI 54–84{\%}) and 71{\%} (95{\%} CI 56–86{\%}). Eight cases were refractory to induction with 1-year OS 20{\%}, and no factors were predictive for primary refractory disease. Of 28 responders, 17 proceeded to transplant while 11 were observed, primarily due to age and co-morbidities. By 24-week landmark analysis after diagnosis, the 2-year PFS and OS were both 94{\%} (95{\%} CI 83–100{\%}) vs 79{\%} (95{\%} CI 52–100{\%}) for transplant vs observation (p = .59 for both PFS and OS). There was no significant benefit to consolidative transplant in our series, and primary refractory DHL needs novel approaches.",
keywords = "autologous transplant, Double hit lymphoma, EPOCH-R",
author = "Andy Chen and Leonard, {Jessica T.} and Craig Okada and Gay, {Nathan D.} and Kari Chansky and Guang Fan and Jennifer Dunlap and Phil Raess and Rita Braziel and Alex Stentz and Richard Maziarz",
year = "2017",
month = "12",
day = "4",
doi = "10.1080/10428194.2017.1406085",
language = "English (US)",
pages = "1--6",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma

AU - Chen, Andy

AU - Leonard, Jessica T.

AU - Okada, Craig

AU - Gay, Nathan D.

AU - Chansky, Kari

AU - Fan, Guang

AU - Dunlap, Jennifer

AU - Raess, Phil

AU - Braziel, Rita

AU - Stentz, Alex

AU - Maziarz, Richard

PY - 2017/12/4

Y1 - 2017/12/4

N2 - High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42% of cases. At median follow-up of 38 months, the 2-year progression free survival (PFS) and overall survival (OS) were 69% (95% CI 54–84%) and 71% (95% CI 56–86%). Eight cases were refractory to induction with 1-year OS 20%, and no factors were predictive for primary refractory disease. Of 28 responders, 17 proceeded to transplant while 11 were observed, primarily due to age and co-morbidities. By 24-week landmark analysis after diagnosis, the 2-year PFS and OS were both 94% (95% CI 83–100%) vs 79% (95% CI 52–100%) for transplant vs observation (p = .59 for both PFS and OS). There was no significant benefit to consolidative transplant in our series, and primary refractory DHL needs novel approaches.

AB - High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42% of cases. At median follow-up of 38 months, the 2-year progression free survival (PFS) and overall survival (OS) were 69% (95% CI 54–84%) and 71% (95% CI 56–86%). Eight cases were refractory to induction with 1-year OS 20%, and no factors were predictive for primary refractory disease. Of 28 responders, 17 proceeded to transplant while 11 were observed, primarily due to age and co-morbidities. By 24-week landmark analysis after diagnosis, the 2-year PFS and OS were both 94% (95% CI 83–100%) vs 79% (95% CI 52–100%) for transplant vs observation (p = .59 for both PFS and OS). There was no significant benefit to consolidative transplant in our series, and primary refractory DHL needs novel approaches.

KW - autologous transplant

KW - Double hit lymphoma

KW - EPOCH-R

UR - http://www.scopus.com/inward/record.url?scp=85036496307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036496307&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1406085

DO - 10.1080/10428194.2017.1406085

M3 - Article

SP - 1

EP - 6

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -